KAZIM MOHAMMED: Open Payments
NPI 1467911040 · FORT MYERS, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,540 in 81 payments from 15 companies in 2025. Trend: 2023 $1,631 · 2024 $2,102 · 2025 $1,540
Food & beverage: $1,540
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $401 |
| ABBVIE INC. | 14 | $186 |
| Supernus Pharmaceuticals, Inc. | 10 | $158 |
| Neurocrine BioSciences, Inc. | 6 | $152 |
| Axsome Therapeutics, Inc. | 6 | $103 |
| Vanda Pharmaceuticals Inc. | 5 | $99 |
| E.R. Squibb & Sons, L.L.C. | 5 | $88 |
| Collegium Pharmaceutical, Inc. | 3 | $60 |
| Corium, LLC | 3 | $58 |
| Janssen Pharmaceuticals, Inc | 3 | $56 |
Products named: CAPLYTA, VRAYLAR, Qelbree, INGREZZA, Auvelity, COBENFY, FANAPT, REXULTI.
Industry payments across FL — which companies pay providers there.
